모노크로탈린으로 유도된 폐동맥고혈압 백서 모델에서 안지오텐신 전환 효소에 대한 Bosentan 치료 효과
Effects of Bosentan Treatment on Angiotensin Converting Enzyme in Monocrotaline Induced Pulmonary Hypertension Rats
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Pulmonary artery hypertension is characterized by persistent increase of vascular resistance, and is associated with right ventricle failure. We investigated changes of plasma renin, serum aldosterone, angiotensin converting enzyme (ACE) concentrations, ACE gene expressions and protein contents after bosentan treatment. Methods: Six-week-old male Sprague-Dawley rats were divided into three groups: control (C) group, monocrotaline (M) group, and bosentan (B) group. Groups M and B were subcutaneously administered with 60 mg/kg of monocrotaline. In group B, 20 mg/kg/day of bosentan was administered by gavage twice a day. The rats were sacrificed after 1, 5, 7, 14, and 28 days. Changes of ACE gene expressions were analyzed by reverse transcription-polymerase chain reaction. Also, plasma renin, serum aldosterone, and ACE levels were measured. Results: Serum aldosterone levels were significantly increased in group M compared with group C and significantly decreased after bosentan treatment on day 28. Serum ACE concentrations were significantly decreased compared with group M after bosentan treatment on day 28. Gene expressions of ACE were significantly increased in group M compared with group C on day 5 and significantly decreased after bosentan treatment on day 7 and 14. ACE protein contents significantly increased in group M compared with group C in week 2 and 4. It significantly decreased after bosentan treatment in week 2. Conclusions: The renin-angiotensin system is associated with pulmonary artery hypertension. To investigate the effects of bosentan on the renin-angiotensin system in pulmonary artery hypertension, further studies on the effects of bosentan according to different doses are required in the future.
Abstract
Background: Pulmonary artery hypertension is characterized by persistent increase of vascular resistance, and is associated with right ventricle failure. We investigated changes of plasma renin, serum aldosterone, angiotensin converting enzyme (ACE) concentrations, ACE gene expressions and protein contents after bosentan treatment. Methods: Six-week-old male Sprague-Dawley rats were divided into three groups: control (C) group, monocrotaline (M) group, and bosentan (B) group. Groups M and B were subcutaneously administered with 60 mg/kg of monocrotaline. In group B, 20 mg/kg/day of bosentan was administered by gavage twice a day. The rats were sacrificed after 1, 5, 7, 14, and 28 days. Changes of ACE gene expressions were analyzed by reverse transcription-polymerase chain reaction. Also, plasma renin, serum aldosterone, and ACE levels were measured. Results: Serum aldosterone levels were significantly increased in group M compared with group C and significantly decreased after bosentan treatment on day 28. Serum ACE concentrations were significantly decreased compared with group M after bosentan treatment on day 28. Gene expressions of ACE were significantly increased in group M compared with group C on day 5 and significantly decreased after bosentan treatment on day 7 and 14. ACE protein contents significantly increased in group M compared with group C in week 2 and 4. It significantly decreased after bosentan treatment in week 2. Conclusions: The renin-angiotensin system is associated with pulmonary artery hypertension. To investigate the effects of bosentan on the renin-angiotensin system in pulmonary artery hypertension, further studies on the effects of bosentan according to different doses are required in the future.
참고문헌 (28)
- Runo JR, "Primary pulmonary hypertension", Lancet, 361, pp.1533~1544 (2003)
- Chan SY, "Pathogenic mechanisms of pulmonary arterial hypertension", Journal of Molecular and Cellular Cardiology, 44, pp.14~30 (2008)
- Minamino T, "Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia", Proceedings of the National Academy of Sciences, 98, pp.8798~8803 (2001)
- Skeggs LT, "Kahn JR. The biochemistry of the renin-angiotensin system", Advances in Experimental Medicine and Biology, 130, pp.1~27 (1980)
- Turner AJ, "The angiotensin-converting enzyme gene family: genomics and pharmacology", Trends in Pharmacological Sciences, 23, pp.177~183 (2002)
- Studdy PR, "Angiotensin-converting enzyme and its clinical significance--a review", Journal of Clinical Pathology, 36, pp.938~947 (1983)
- Orte C, "Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension", Journal of Pathology, 192, pp.379~384 (2000)
- Cargill RI, "The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature", British Journal of Clinical Pharmacology, 40, pp.11~18 (1995)
- Dezso B, "Identification of renin in resident alveolar macrophages and monocytes: HPLC and immunohistochemical study", Journal of Cell Science, 91(1), pp.155~159 (1988)
- Ohkubo H, "Tissue distribution of rat angiotensinogen mRNA and structural analysis of its heterogeneity", The Journal of Biological Chemistry, 261, pp.319~323 (1986)
- Andersen K, "Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension", Clinical Interventions in Aging, 4, pp.137~151 (2009)
- 오석, "Evidence for Angiotensin-converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary Hypertension", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 179(11), pp.1048~1054, AMER THORACIC SOC
- Wilson DW, "Mechanisms and pathology of monocrotaline pulmonary toxicity", Critical Reviews in Toxicology, 22, pp.307~325 (1992)
- Todd L, "Pulmonary toxicity of monocrotaline differs at critical periods of lung development", Pediatrics in Review, 19, pp.731~737 (1985)
- Weber C, "Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects", Clinical Pharmacology & Therapeutics, 60, pp.124~137 (1996)
- 임경아, "Monocrotaline으로 유발한 백서 폐동맥 고혈압에서 Endothelin 수용체 차단제 투여의 효과", Korean Journal of Pediatrics, 52(6), pp.689~695 (2009), 대한소아과학회
- 임경아, "Gene Expression of Endothelin-1 and Endothelin Receptor A on Monocrotaline-Induced Pulmonary Hypertension in Rats After Bosentan Treatment", Korean Circulation Journal, 40(09), pp.459~464 (2010), 대한심장학회
- 구희선, "Gene Expressions of Nitric Oxide Synthase and Matrix Metalloproteinase-2 in Monocrotaline-Induced Pulmonary Hypertension in Rats After Bosentan Treatment", Korean Circulation Journal, 41(2), pp.83~90 (2011), 대한심장학회
- Kuba K, "Angiotensin-converting enzyme 2 in lung diseases", Current Opinion in Pharmacology, 6, pp.271~276 (2006)
- Morrell NW, "Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension", American Journal of Physiology, 269, pp.1186~1194 (1995)
- Kanazawa H, "Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease", American Journal of Respiratory and Critical Care Medicine, 162, pp.1235~1238 (2000)
- van Suylen RJ, "The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease", American Journal of Respiratory and Critical Care Medicine, 159, pp.1791~1795 (1999)
- Kay JM, "Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension", Thorax, 37, pp.88~96 (1982)
- Lafranconi WM, "Changes in angiotensinconverting enzyme activity in lungs damaged by the pyrrolizidine alkaloid monocrotaline", Thorax, 38, pp.307~309 (1983)
- Molteni A, "Monocrotaline-induced pulmonary endothelial dysfunction in rats", Proceedings of the Society for Experimental Biology and Medicine, 176, pp.88~94 (1984)
- Cassis L, "Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension", Biochemical Pharmacology, 54, pp.27~31 (1997)
- 오석, "Prevention of Pulmonary Hypertension by Angiotensin-Converting Enzyme 2 Gene Transfer", HYPERTENSION, 54(2), pp.365~371, LIPPINCOTT WILLIAMS WILKINS
- Jeffery TK, "Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension", Pharmacology & Therapeutics, 92, pp.1~20 (2001)